JMP Securities analyst Devin Ryan maintains Carlyle Group (NASDAQ:CG) with a Market Outperform and lowers the price target from $60 to $58.
EXCLUSIVE: ‘Prescription Erectile Dysfunction Market Could Triple If an ED Therapy Is Made Available OTC,’ Petros Pharma President Says
Petros Pharmaceuticals specializes in men's health therapeutics. President Fady Boctor discusses the company's strategy to make key prescription medications. Petros is poised to expand within the $66.5 billion Rx-to-OTC market projected by 2033.
